Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Zevra Therapeutics (ZVRA) over the last 7 years, with Q3 2025 value amounting to $145.1 million.

  • Zevra Therapeutics' Short-term Investments rose 31053.29% to $145.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.1 million, marking a year-over-year increase of 31053.29%. This contributed to the annual value of $35.7 million for FY2024, which is 4464.92% up from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Short-term Investments is $145.1 million, which was up 31053.29% from $154.9 million recorded in Q2 2025.
  • Zevra Therapeutics' Short-term Investments' 5-year high stood at $154.9 million during Q2 2025, with a 5-year trough of $1.3 million in Q1 2022.
  • Its 4-year average for Short-term Investments is $37.6 million, with a median of $24.7 million in 2023.
  • Its Short-term Investments has fluctuated over the past 5 years, first surged by 247122.57% in 2023, then tumbled by 7131.65% in 2024.
  • Quarter analysis of 4 years shows Zevra Therapeutics' Short-term Investments stood at $16.9 million in 2022, then surged by 46.08% to $24.7 million in 2023, then skyrocketed by 44.65% to $35.7 million in 2024, then soared by 306.23% to $145.1 million in 2025.
  • Its Short-term Investments stands at $145.1 million for Q3 2025, versus $154.9 million for Q2 2025 and $25.3 million for Q1 2025.